Exjade Tablet For Oral Suspension 125Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Exjade: Tablet for oral suspension (125mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

DEFERASIROX (de FER a sir ox) binds to iron in the blood. It helps to prevent and treat too much iron in the blood caused by blood transfusions.

In-Depth Information

Exjade 125mg Tablet for Suspension

NDC: 000780468
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Transfusional Iron Overload, Iron Toxicity

Storage Information
Protect from moisture
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Exjade 125mg Tablet for Suspension

Reported Side Effects for Exjade 125mg Tablet for Suspension

Inflamed Optic Nerve Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Throat Inflammation Incidence:
<0.1%*
Severity: MODERATE
Onset: DELAYED
Erythema Multiforme Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Stomach Ulcer Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Deafness Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Fanconi'S Syndrome Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Visual Impairment Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Lightheadedness Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Inflamed Pancreas Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Intestinal Bleeding Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Cataracts Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Inability To Sleep Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Inflamed Stomach Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Fever Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Swelling Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.0-8.4%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
8.0-13.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
10.1-21.2%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
10.5-26.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
11.8-47.0%*
Severity: MILD
Onset: EARLY
Protein In The Urine Incidence:
18.3%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
21.3-28.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Exjade 125mg Tablet for Suspension

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Food and Exjade 125mg Tablet for Suspension(Deferasirox)
Food and Deferasirox(Deferasirox)
Take Deferasirox with water or juice only, on an empty stomach. Taking this drug with food may change how well it works for you. It is recommended to take Deferasirox at least 30 minutes before any other beverage, food, or other medication for the day.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Exjade

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5